8-K: Matinas BioPharma Faces NYSE American Delisting Warning

Matinas BioPharma Holdings, Inc. received a notice from NYSE American for failing to meet continued listing standards, with a deadline to submit a compliance plan.

Summary

• Matinas BioPharma Holdings, Inc. received a written notice from NYSE American on April 2, 2026, indicating non-compliance with continued listing standards.
• The non-compliance stems from failing to meet minimum stockholders' equity requirements, having reported losses in the last five fiscal years ending December 31, 2025.
• As of December 31, 2025, the Company's stockholders' equity was $4.83 million.
• The Company has until May 2, 2026, to submit a plan to regain compliance.
• If the plan is accepted, the Company may have up to 18 months to regain compliance, subject to quarterly monitoring.
• Failure to regain compliance or have the plan accepted could lead to delisting proceedings.
• The notice does not immediately impact the trading of the Company's common stock on NYSE American or its ongoing business operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the immediate threat of delisting and the underlying financial struggles indicated by sustained losses and low equity.

Positives

• The Company's shares will continue to be listed and traded on the NYSE American without immediate impact.
• The Company has a period of up to 18 months to regain compliance if its plan is accepted.
• The Company intends to submit a plan to regain compliance with NYSE American listing standards.
• The notice does not affect the Company's ongoing business operations or its SEC reporting requirements.

Negatives

• The Company is not in compliance with NYSE American continued listing standards related to stockholders' equity and sustained losses.
• The Company has reported losses for the five most recent fiscal years ending December 31, 2025.
• The Company's stockholders' equity of $4.83 million as of December 31, 2025, falls below certain thresholds required by NYSE American.
• There is no assurance that the Company will be able to achieve compliance within the cure period.
• Delisting proceedings will commence if the Company's plan to regain compliance is not accepted by NYSE American.
• The independent auditor's report includes an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.

Risks

• Potential delisting from the NYSE American if a compliance plan is not accepted or if compliance is not achieved within the cure period.
• Substantial doubt about the Company's ability to continue as a going concern, as noted by the independent auditor.
• Uncertainty regarding the acceptance of the Company's plan to regain compliance by the NYSE American.
• The possibility of ongoing business operations being negatively affected by the delisting threat, despite current assurances.

Future Outlook

The Company intends to submit a plan to regain compliance with NYSE American listing standards and may be eligible for up to 18 months to achieve compliance if the plan is accepted. However, there is no assurance of success.

Management Comments

• The Company intends to submit the Plan to regain compliance with NYSE American listing standards.
• There can be no assurance that the Company will be able to achieve compliance with such standards within the Cure Period.

Industry Context

StockSavvy.ai notes that delisting notices due to sustained losses and low equity are a significant concern for smaller biopharmaceutical companies, especially those reliant on external funding and facing lengthy development timelines. Competitors in this space often face similar pressures, making robust financial management and clear communication with exchanges critical.

Stakeholder Impact

• Shareholders: Potential for share price volatility and the risk of delisting from a major exchange, which could reduce liquidity and investor confidence.
• Creditors: Increased risk if the company faces delisting and struggles to maintain operations or secure financing.
• Employees: Potential impact on morale and job security if the company's financial situation deteriorates further or if delisting occurs.

Next Steps

• Submit a plan of actions to regain compliance with NYSE American listing standards by May 2, 2026.
• Undergo periodic reviews and quarterly monitoring if the plan is accepted by NYSE American.
• Potentially appeal a staff delisting determination if the plan is not accepted and delisting proceedings commence.

Key Dates

Recommendation

The filing indicates a significant risk of delisting due to non-compliance with NYSE American listing standards. While the company has a plan to address this, there is no assurance of success. Existing investors should hold to see if the compliance plan is accepted and if the company can regain compliance, while new investors should exercise extreme caution due to the heightened risk profile.

Keywords

Matinas BioPharma, NYSE American, Listing Standards, Delisting, Compliance Plan, Stockholders Equity, Form 8-K, Biopharmaceutical